Product Code: PM3738
The global cancer biomarkers market size is expected to reach USD 53.36 billion by 2032, according to a new study by Polaris market research. The report "Cancer Biomarkers Market Share, Size, Trends, Industry Analysis Report, By Type (Breast, Prostate, Colorectal, Cervical, Liver, Lung Cancer), By Biomolecule (Genetic, Epigenetic, Metabolic, Proteomic), By Application, And Segment Forecasts, 2023-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Increasing initiatives and investments in the development of drugs that target novel cancer biomarkers play a crucial role in driving the growth potential of the cancer biomarkers market. These biomarkers serve as indicators of specific characteristics of cancer cells, enabling the development of more targeted and effective treatments. By focusing on these unique biomarkers, pharmaceutical companies can create drugs tailored to specific subtypes of cancer, leading to improved treatment outcomes and reduced side effects.
Moreover, the introduction of technologically advanced companion diagnostic kits complements the development of targeted therapies. These diagnostic kits help identify the presence of specific biomarkers in patients, allowing healthcare professionals to personalize treatment plans based on individual patient profiles. Personalized medicine, guided by these diagnostic kits, ensures that patients receive the most suitable treatments, leading to better treatment responses and enhanced overall patient outcomes.
Growth is also facilitated by the existence of supportive government initiatives aimed at advancing novel cancer diagnostic techniques. For instance, the National Cancer Institute (NCI) allocates funding to over 8 research areas specifically focused on the development of cancer biomarkers. Other organizations such as Cancer Research UK, Lung Cancer Research Foundation, and National Institutes of Health also play a significant role by providing funding for research projects centered around biomarkers. These initiatives foster innovation and research in the field, accelerating the progress of new and improved cancer diagnostic techniques.
Individuals who engage in high alcohol consumption, use tobacco, have unhealthy dietary habits, and lead a sedentary lifestyle are found to be 80% more susceptible to developing cancer compared to those with healthier habits. Additionally, certain infections, including Human papillomavirus (HPV), Epstein-Barr virus, Hepatitis B virus, and Helicobacter pylori, have also been under study for their potential association with cancer development.
Cancer Biomarkers Market Report Highlights
Breast cancer held the largest share, owing to the rising cases of breast cancer, extensive research on biomarkers, & key product launches
Genetic biomarkers will grow at the rapid pace, because of rising cases of genetic disorders, and relevant diseased scenario
Personalized medicine will grow at rapid pace, owing recent advancements in personalized treatment options
North America held the largest share of the market in 2022, owing to consumer awareness, presence of skilled surgeons with better healthcare infrastructure
Key players include Abbott Laboratories, Thermo Fisher Scientific, Affymetrix, Illumina, Agilent Technologies, Merck, Hologic, Roche, QIAGEN, Sino Biological, & Becton
Polaris market research has segmented the cancer biomarkers market report based on type, biomolecule, application, and region:
Cancer Biomarkers, Type Outlook (Revenue - USD Billion, 2023 - 2032)
- Breast cancer
- Prostate cancer
- Colorectal cancer
- Cervical cancer
- Liver cancer
- Lung cancer
- Others
Cancer Biomarkers, Biomolecule Outlook (Revenue - USD Billion, 2023 - 2032)
- Genetic Biomarkers
- Epigenetic Biomarkers
- Metabolic Biomarkers
- Proteomic Biomarkers
- Others
Cancer Biomarkers, Application Outlook (Revenue - USD Billion, 2023 - 2032)
- Drug discovery and Development
- Diagnostics
- Personalized medicine
- Others
Cancer Biomarkers, Regional Outlook (Revenue - USD Billion, 2023 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
3. Research Methodology
- 3.1. Overview
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Cancer Biomarkers Market Insights
- 4.1. Cancer Biomarkers Market - Biomolecule Snapshot
- 4.2. Cancer Biomarkers Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing awareness among patients and healthcare professionals about the importance of early diagnosis of malignancies.
- 4.2.1.2. Rising demand for personalized medicine
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High capital investment
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Cancer Biomarkers Market Biomolecule Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Cancer Biomarkers Market, by Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 5.3. Breast cancer
- 5.3.1. Global Cancer Biomarkers Market, by Breast cancer, by Region, 2019-2032 (USD Billion)
- 5.4. Prostate cancer
- 5.4.1. Global Cancer Biomarkers Market, by Prostate cancer, by Region, 2019-2032 (USD Billion)
- 5.5. Colorectal cancer
- 5.5.1. Global Cancer Biomarkers Market, by Colorectal cancer, by Region, 2019-2032 (USD Billion)
- 5.6. Cervical cancer
- 5.6.1. Global Cancer Biomarkers Market, by Cervical cancer, by Region, 2019-2032 (USD Billion)
- 5.7. Liver cancer
- 5.7.1. Global Cancer Biomarkers Market, by Liver cancer, by Region, 2019-2032 (USD Billion)
- 5.8. Lung cancer
- 5.8.1. Global Cancer Biomarkers Market, by Lung cancer, by Region, 2019-2032 (USD Billion)
- 5.9. Others
- 5.9.1. Global Cancer Biomarkers Market, by Others, by Region, 2019-2032 (USD Billion)
6. Global Cancer Biomarkers Market, by Application
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 6.3. Drug discovery and Development
- 6.3.1. Global Cancer Biomarkers Market, by Drug discovery and Development, by Region, 2019-2032 (USD Billion)
- 6.4. Diagnostics
- 6.4.1. Global Cancer Biomarkers Market, by Diagnostics, by Region, 2019-2032 (USD Billion)
- 6.5. Personalized medicine
- 6.5.1. Global Cancer Biomarkers Market, by Personalized medicine, by Region, 2019-2032 (USD Billion)
- 6.6. Others
- 6.6.1. Global Cancer Biomarkers Market, by Others, by Region, 2019-2032 (USD Billion)
7. Global Cancer Biomarkers Market, by Biomolecule
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 7.3. Genetic Biomarkers
- 7.3.1. Global Cancer Biomarkers Market, by Genetic Biomarkers, By Region, 2019-2032 (USD Billion)
- 7.4. Epigenetic Biomarkers
- 7.4.1. Global Cancer Biomarkers Market, by Epigenetic Biomarkers, By Region, 2019-2032 (USD Billion)
- 7.5. Metabolic Biomarkers
- 7.5.1. Global Cancer Biomarkers Market, by Metabolic Biomarkers, By Region, 2019-2032 (USD Billion)
- 7.6. Proteomic Biomarkers
- 7.6.1. Global Cancer Biomarkers Market, by Proteomic Biomarkers, By Region, 2019-2032 (USD Billion)
- 7.7. Others
- 7.7.1. Global Cancer Biomarkers Market, by Others, By Region, 2019-2032 (USD Billion)
8. Global Cancer Biomarkers Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Cancer Biomarkers Market Assessment, By Geography, 2019-2032 (USD Billion)
- 8.3. Cancer Biomarkers Market - North America
- 8.3.1. North America: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.3.2. North America: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.3.3. North America: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.3.4. Cancer Biomarkers Market - U.S.
- 8.3.4.1. U.S.: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.3.4.2. U.S.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.3.4.3. U.S.: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.3.5. Cancer Biomarkers Market - Canada
- 8.3.5.1. Canada: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.3.5.2. Canada.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.3.5.3. Canada: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.4. Cancer Biomarkers Market - Europe
- 8.4.1. Europe: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.4.2. Europe.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.4.3. Europe: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.4.4. Cancer Biomarkers Market - UK
- 8.4.4.1. UK: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.4.4.2. UK.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.4.4.3. UK: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.4.5. Cancer Biomarkers Market - France
- 8.4.5.1. France: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.4.5.2. France.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.4.5.3. France: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.4.6. Cancer Biomarkers Market - Germany
- 8.4.6.1. Germany: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.4.6.2. Germany.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.4.6.3. Germany: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.4.7. Cancer Biomarkers Market - Italy
- 8.4.7.1. Italy: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.4.7.2. Italy.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.4.7.3. Italy: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.4.8. Cancer Biomarkers Market - Spain
- 8.4.8.1. Spain: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.4.8.2. Spain.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.4.8.3. Spain: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.4.9. Cancer Biomarkers Market - Netherlands
- 8.4.9.1. Netherlands: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.4.9.2. Netherlands.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.4.9.3. Netherlands: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.4.10. Cancer Biomarkers Market - Russia
- 8.4.10.1. Russia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.4.10.2. Russia.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.4.10.3. Russia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.5. Cancer Biomarkers Market - Asia Pacific
- 8.5.1. Asia Pacific: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.5.2. Asia Pacific.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.5.3. Asia Pacific: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.5.4. Cancer Biomarkers Market - China
- 8.5.4.1. China: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.5.4.2. China.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.5.4.3. China: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.5.5. Cancer Biomarkers Market - India
- 8.5.5.1. India: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.5.5.2. India.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.5.5.3. India: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.5.6. Cancer Biomarkers Market - Malaysia
- 8.5.6.1. Malaysia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.5.6.2. Malaysia.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.5.6.3. Malaysia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.5.7. Cancer Biomarkers Market - Japan
- 8.5.7.1. Japan: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.5.7.2. Japan.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.5.7.3. Japan: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.5.8. Cancer Biomarkers Market - Indonesia
- 8.5.8.1. Indonesia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.5.8.2. Indonesia.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.5.8.3. Indonesia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.5.9. Cancer Biomarkers Market - South Korea
- 8.5.9.1. South Korea: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.5.9.2. South Korea.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.5.9.3. South Korea: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.6. Cancer Biomarkers Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.6.2. Middle East & Africa.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.6.3. Middle East & Africa: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.6.4. Cancer Biomarkers Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.6.4.2. Saudi Arabia.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.6.4.3. Saudi Arabia: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.6.5. Cancer Biomarkers Market - UAE
- 8.6.5.1. UAE: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.6.5.2. UAE.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.6.5.3. UAE: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.6.6. Cancer Biomarkers Market - Israel
- 8.6.6.1. Israel: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.6.6.2. Israel.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.6.6.3. Israel: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.6.7. Cancer Biomarkers Market - South Africa
- 8.6.7.1. South Africa: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.6.7.2. South Africa.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.6.7.3. South Africa: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.7. Cancer Biomarkers Market - Latin America
- 8.7.1. Latin America: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.7.2. Latin America.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.7.3. Latin America: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.7.4. Cancer Biomarkers Market - Mexico
- 8.7.4.1. Mexico: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.7.4.2. Mexico.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.7.4.3. Mexico: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.7.5. Cancer Biomarkers Market - Brazil
- 8.7.5.1. Brazil: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.7.5.2. Brazil.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.7.5.3. Brazil: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
- 8.7.6. Cancer Biomarkers Market - Argentina
- 8.7.6.1. Argentina: Cancer Biomarkers Market, by Type, 2019-2032 (USD Billion)
- 8.7.6.2. Argentina.: Cancer Biomarkers Market, by Biomolecule, 2019-2032 (USD Billion)
- 8.7.6.3. Argentina: Cancer Biomarkers Market, by Application, 2019-2032 (USD Billion)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Abbott Laboratories
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Agilent Technologies
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Affymetrix
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Becton
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Hologic
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Illumina
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Merck
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. QIAGEN
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Roche
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Sino Biological
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. Thermo Fisher Scientific
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development